Stock Screener App

Frei -

Installieren

2.1629

2.95% -0.0671

Lexicon Pharmaceuticals Inc (LXRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt LXRX? Forum Prognose Aktiensplit

Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten

Heart Failure Trial Data Might Change The Case For Investing In Lexicon Pharmaceuticals (LXRX) - simplywall.st

Lexicon Pharmaceuticals Stock Price Forecast. Should You Buy LXRX? - StockInvest.us

Here's Why You Should Add LXRX Stock to Your Portfolio Now - Eastern Progress

Lexicon Pharmaceuticals Inc (LXRX) Valuation: PE, PB & Fair Value Analysis - TradingKey

LXRX|Lexicon Pharmaceuticals Inc|Price:2.240|Chg%:-0.020 - TradingKey

Three New York investor conferences will hear from Lexicon - Stock Titan

Lexicon Pharmaceuticals (LXRX) Posts Positive Heart Failure Tria - GuruFocus

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure - Yahoo Finance

Sotagliflozin Linked to Fewer Heart-Failure Events in Patients With BP as Low as 100 - Stock Titan

Lexicon Pharmaceuticals Inc. (LXRX) Key Financial Ratios – Valuation, Profitability & More - Value Research

Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk - marketscreener.com

Lexicon Pharmaceuticals (LXRX) Advances Obesity Drug Trial, Faces Valuation Challenges - GuruFocus

Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851 - marketscreener.com

LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon - finance.yahoo.com

The Bull Case For Lexicon Pharmaceuticals (LXRX) Could Change Following Steep Q2 Revenue Drop And Loss Shift - simplywall.st

Lexicon (LXRX) Levels: Slides 0.41% to $2.41 in the Current Update; Technical Setup - vinanet.vn

Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets (NASDAQ:LXRX) - Seeking Alpha

Lexicon Pharmaceuticals Inc (LXRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

LEXICON PHARMACEUTICALS INC (LXRX) Stock Chart - ChartMill

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving AverageHere's Why - MarketBeat

LEXICON PHARMACEUTICALS, INC. SEC Filing (Aug 17, 2026) - Stock Titan

Lexicon Pharmaceuticals (LXRX) Trading Near $2.34: Support and Resistance Define Near-Term RangeGamma Squeeze - vinanet.vn

Is Lexicon’s Earnings Slide And New Share Shelf Altering The Investment Case For Lexicon Pharmaceuticals (LXRX)? - simplywall.st

Lexicon Pharmaceuticals (STU:LX31) EV-to-OCF : -14.01 (As of Aug. 15, 2026) - GuruFocus

Analysts Have Made A Financial Statement On Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Second-Quarter Report - simplywall.st

Lexicon Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-08-10 - Seeking Alpha

Renaissance Technologies LLC Increases Holdings in Lexicon Pharmaceuticals, Inc. $LXRX - MarketBeat

HC Wainwright Issues Positive Forecast for LXRX Earnings - MarketBeat

Lexicon Pharmaceuticals, Inc. (LXRX) stock price, news, quote and history - Yahoo Finance UK

Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat

Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo

Lexicon Pharmaceuticals (NASDAQ:LXRX) Announces Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat

Why Lexicon Pharmaceuticals (LXRX) Is Up 6.9% After Q2 Revenue Collapse And New Shelf Filings - Yahoo Finance

Lexicon Pharmaceuticals Inc (LXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Lexicon Pharmaceuticals (LXRX) Stockholders Plan to Sell 1.26M S - GuruFocus

Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highl - GuruFocus

Lexicon Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $3.86, Implies 57% Upside - TradingView

Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highlights: Zynquista NDA ... - Yahoo Finance

Lexicon Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat

Lexicon Pharmaceuticals (Nasdaq: LXRX) files shelf to register 1.26M warrant shares - Stock Titan

H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6 - moomoo.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Down on Disappointing Earnings - MarketBeat

FMR LLC (LXRX) discloses 11.7% Lexicon Pharmaceuticals stake in amended 13G - Stock Titan

Is Lexicon Pharmaceuticals (LXRX) Facing Challenges After Q2 Ear - GuruFocus

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Lexicon Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, vs. FactSet Est of $0.05 Loss - marketscreener.com

Earnings Flash (LXRX) Lexicon Pharmaceuticals, Inc. Reports Q2 Revenue $692,000, vs. FactSet Est of $4.0M - marketscreener.com

Lexicon: Q2 Earnings Snapshot - marketscreener.com

Lexicon Pharmaceuticals posts Q2 net loss - TradingView

Lexicon Pharmaceuticals Q2 revenue falls to $0.7 million amid clinical updates - Quiver Quantitative

Lexicon Pharmaceuticals Reports Q2 2026 Results; Completes Enrollment in Phase 3 SONATA-HCM Study and Advances ZYNQUISTA NDA Resubmission - Quiver Quantitative

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates - The Manila Times

Lexicon Pharma (Nasdaq: LXRX) swings to $31.8M Q2 2026 loss - Stock Titan

BRIEF-Lexicon Pharmaceuticals Q2 EPS USD -0.07 - TradingView

Press Release: Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates - webull.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Lowered by Zacks Research - MarketBeat

Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a shareEarnings Preview - TradingView

Lexicon Pharmaceuticals (LXRX) Slips 1.28% as Shares Hold Above Key SupportLiquidity Order Flow - dars.gov.et

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 - The Manila Times

Lexicon schedules Aug. 6 call and webcast for Q2 results - Stock Titan

RPRX

$60.18

0.69%

INSM

$129.33

3.67%

ROIV

$41.77

0.78%

ALNY

$255.60

1.73%

ONC

$350.10

0.47%

RVMD

$209.70

1.11%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters